FIBROBODY
LIVE

Serial Number

79321550

Owner

LinXis B.V.

Filing Date

Feb 18, 2021

Add to watchlist:

No watchlists yet
View on USPTO

FIBROBODY Trademark

Serial Number: 79321550 • Registration: 6624524

FIBROBODY is a trademark filed by LinXis B.V. on February 18, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

LinXis B.V. (4 trademarks)

Cronenburg 152

Entity Type: 16

Trademark Details

Filing Date

February 18, 2021

Registration Date

January 25, 2022

Published for Opposition

November 9, 2021

Goods & Services

Pharmaceutical preparations for the treatment of fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; drug delivery agents in the form of parenteral formulations and per-oral formulations, tablets and capsules that facilitate the delivery of pharmaceutical preparations; pharmaceutical drugs for the treatment of fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; drug delivery agents in the form of parenteral formulations and per-oral formulations, tablets and capsules that facilitate the delivery of pharmaceutical preparations; biochemical medicines for the treatment of fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; chemical preparations for pharmaceutical purposes, namely, for the treatment of fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; diagnostic agents for pharmaceutical purposes; pharmaceutical substances and preparations for the treatment of fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; drug delivery agents consisting of compounds that facilitate delivery of pharmaceutical preparations

Chemical additives for use in the manufacture of pharmaceuticals; chemical preparations for use in the manufacture of pharmaceuticals; active chemical ingredients for use in the manufacture of pharmaceuticals for treating fibrotic disease, liver- kidney- and lung fibrosis, inflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease

Medical services, namely, in vitro analysis for medical and pharmaceutical use; medical services, namely, in vitro testing for medical and pharmaceutical use; consultancy and information services provided via the internet relating to pharmaceutical products

Pharmaceutical research services; conducting clinical trials for others relating to pharmaceuticals; pharmaceutical research and development; pharmaceutical product evaluation; consultancy relating to pharmaceutical research and development; laboratory research services relating to pharmaceuticals; providing information about the results of clinical trials for pharmaceuticals; providing information about medical and scientific research in the field of pharmaceuticals; scientific research services in the field of proteins, antibodies, microorganisms and cells; research and development services in the field of antibody technology; design and development of medical technology

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Sep 19, 2025 NREP
CHANGE OF NAME/ADDRESS REC'D FROM IB
Mar 14, 2025 ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
Sep 20, 2024 ADCH
NOTIFICATION PROCESSED BY IB
Jun 5, 2022 GPNX
FINAL DISPOSITION NOTICE SENT TO IB
May 19, 2022 FICS
FINAL DISPOSITION PROCESSED
May 18, 2022 FIMP
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Feb 24, 2022 GPAR
REGISTERED-PRINCIPAL REGISTER
Jan 25, 2022 R.PR
PUBLISHED FOR OPPOSITION
Nov 9, 2021 PUBO
NOTICE OF PUBLICATION
Oct 20, 2021 NPUB
APPLICATION FILING RECEIPT MAILED
Oct 12, 2021 MAFR
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 6, 2021 CNSA
ASSIGNED TO EXAMINER
Oct 6, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 6, 2021 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Oct 4, 2021 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 30, 2021 REPR